Goldman Sachs Maintains Buy on Exact Sciences, Lowers Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes has maintained a 'Buy' rating on Exact Sciences (NASDAQ:EXAS), but lowered the price target from $100 to $90.
November 03, 2023 | 2:34 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs has maintained a 'Buy' rating on Exact Sciences, but lowered the price target from $100 to $90.
The news is directly related to Exact Sciences and is likely to influence investor sentiment. While the 'Buy' rating is maintained, the lowering of the price target may indicate a potential downside, which could lead to mixed reactions in the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100